Viromed Medical AG has successfully completed a capital increase announced earlier, placing 450,000 new registered no-par value shares at a price of EUR 4.50 per share. The move yields gross proceeds of approximately EUR 2 million, which the company says will be used to finance working capital. The transaction, reported via NEWMEDIAWIRE, underscores the company's effort to secure liquidity as it pursues growth in the medical technology sector.
The capital increase was executed by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights. Subject to registration in the commercial register, the share capital will rise from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The placement price of EUR 4.50 per share represents a key detail for investors, as it sets a reference point for the company's valuation at the time of issuance.
Why does this matter? For a company focused on the development, manufacture, and distribution of medical products, access to working capital is critical for day-to-day operations and for scaling innovative technologies. Viromed Medical AG, listed on the stock exchange since October 2022, specializes in cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. The fresh funds provide the company with additional financial flexibility to support its operating business and to further advance the use of cold plasma technology in medicine.
The exclusion of subscription rights means existing shareholders did not have the opportunity to participate in the offering on a pro-rata basis. Such an approach can streamline the capital-raising process and attract new investors, but it may also dilute existing holdings. The successful placement of all 450,000 shares at EUR 4.50 suggests sufficient demand from investors, which can be seen as a signal of confidence in Viromed's business model and growth prospects.
Viromed can draw on a broad customer base in the DACH region and beyond, and it aims to realize corresponding growth potential in the coming years. The capital increase, though modest in size, is a strategic step to ensure the company has the necessary resources to execute its plans. More details about the company are available at www.viromed-medical-ag.de, and the original release can be viewed on www.newmediawire.com.
Overall, the completion of the capital increase bolsters Viromed's balance sheet and provides the financial runway to support its working capital needs. As the company continues to promote cold plasma technology in medicine, the additional funds may help it capitalize on market opportunities and drive future growth.
